Large MedTech operating companies sit at the center of complex global ecosystems—balancing R&D productivity, regulatory rigor, manufacturing scale, and commercial execution across diverse markets. In this M&A and partnerships-focused discussion, senior leaders from established operators unpack where innovation truly matters inside large organizations, how priorities are set, and what it takes to move from promising technology to scaled impact across portfolios and geographies.

•Where are large MedTech incumbents actively looking to acquire, partner, or invest today—and why?
•What clinical, commercial, or strategic gaps are driving current M&A and BD roadmaps?
•What signals differentiate a “must-buy” asset from a technology that remains a long-term partnership or pilot?
•How do incumbents evaluate build vs. buy vs. partner decisions across platforms, point solutions, and enabling technologies?
•What are the most common deal-breakers that stall or kill acquisition discussions?
•How do large operators assess scalability, reimbursement readiness, and integration risk before moving forward?
•What should founders understand about timing, internal champions, and proof points to align with acquisition windows?

Learn the details of HistoSonics’ majority stake acquisition by a group of globally recognized private and public investors.

Evidence generation is a critical driver of reimbursement and commercial success in Medtech. Too often, studies are designed to achieve FDA approval but fall short of supporting payer coverage and wide-spread adoption. This panel explores how companies, payers, and investors think about evidence across the product lifecycle—and how FDA strategies, CMS fit-for-purpose studies, and real-world evidence can better align reimbursement strategy with commercialization goals.

• What types of evidence matter most to commercial and government payers when making coverage and reimbursement decisions?

• How early should Medtech companies align evidence generation with reimbursement and commercial strategy?

• Where do companies most often fall short in generating evidence that supports coverage?

• How are real-world evidence and alternative study designs influencing payer adoption today?

• What practical steps can companies take to better align evidence generation, reimbursement, and go-to-market strategy?

Reaching mid-stage is a defining milestone for Medtech companies—but scaling beyond it presents new operational, regulatory, and capital challenges. This CEO-led discussion explores the decisions, tradeoffs, and inflection points that shaped their growth, including how geography, talent hubs, and ecosystem support influenced their trajectory.